Esperion Therapeutics (NASDAQ: ESPR) reported Q1 EPS of $0.34, $0.29 better than the analyst estimate of $0.05. Revenue for the quarter came in at $137.7 million versus the consensus estimate of $84.56 million.

Outlook:
The Company still expects full year 2024 operating expenses to be approximately $225 million to $245 million, including $20 million in non-cash expenses related to stock compensation.

For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.